Professor Matthias Augustin highlights the role of type 2 inflammation in chronic itch across distinct pruritic skin diseases and the cumulative burden of chronic itch and skin lesions in PN.
This symposium delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid. It highlights both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies through a series of engaging panel discussions with Drs Eichenfield, Elmariah, Culton, and Hawkes.

Learn about type 2 inflammation as a driver of neurosensitization and chronic itch in atopic dermatitis with this educational tool.
Prof. Vibeke Backer provides an insightful presentation on the association of type 2 inflammation and the pathogenesis and management of severe and uncontrolled CRSwNP.

Learn about the significant burden that patients with EoE experience, and the role of type 2 inflammation in this chronic, progressive disease.
Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.
Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.

Unlock new perspectives on managing chronic airway diseases. Profs. Leonard Bacharier, Eugenio De Corso, Stella Lee, Marc Miravitlles, Celeste Porsbjerg, Klaus Rabe, and Martin Wagenmann – share their collective wisdom and experience on the evolving landscape of therapeutic strategies aimed at truly modifying disease progression, offering renewed hope for patients and practitioners alike.

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

Dr. Eugene Bleecker presents the utility of FeNO as a biomarker of type 2 inflammation, and its role in the disease burden of asthma.